Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Suspended in Europe Increased risk of skin cancers. [26] [27] Iodinated casein strophantin: 1964 US Metabolic reaction. [3] Iproniazid: 1964 Canada Interactions with food products containing tyrosine. [28] Isaxonine phosphate: 1984 France Hepatotoxicity. [3] Isoxicam: 1983 France, Germany, Spain, others Stevens–Johnson syndrome. [3] Kava Kava ...
Pharmaceutical companies argue that the prices they set for a drug are necessary to fund research. High drug prices can sometimes be a necessity to finance the high-risk and high-cost nature of pharmaceutical R&D. [93] 11% of drug candidates that enter clinical trials are successful and receive approval for sale. [94]
For premium support please call: 800-290-4726 more ways to reach us
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) give new meaning to the word "unstoppable" in the context of pharma stocks. Whereas the total return of Lilly's shares soared by 245% over the ...
CytRx Corp. is a biopharmaceutical research and development oncology company based in Los Angeles, California. The CytRx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin. Aldoxorubicin (formerly INNO-206) is a modified form of doxorubicin, the popular anthracycline chemotherapeutic agent known as "red death".
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in San Diego, California. [4] Founded in 1987 as Progenix Inc., the company went public in 1992.. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and ...